vTv Therapeutics Inc

vTv Therapeutics announced that Chief Medical Officer Thomas Strack presented new research on hypoglycemia-related burdens among adults with type 1 diabetes using automated insulin delivery systems at the inaugural Breakthrough T1D Clinical & Research Congress in Philadelphia. The study, commissioned by vTv and conducted by dQ&A Market Research, surveyed 674 adults with type 1 diabetes, of whom 429 were using automated insulin delivery systems. Among those AID users, 24% reported frequent Level 2 hypoglycemia, 12% reported a Level 3 event in the past 12 months, and 17% reported impaired awareness of hypoglycemia. After accounting for overlap across segments and weighting for A1C, approximately 54% of adults with type 1 diabetes using an AID system were estimated to experience at least one of four hypoglycemia-related burden dimensions. The research supports vTv's cadisegliatin, a potential first-in-class oral liver-selective glucokinase activator being evaluated as an adjunctive therapy to insulin for type 1 diabetes, which has received Breakthrough Therapy designation from the U.S. Food and Drug Administration.

The US FDA has granted orphan drug designation to vTv Therapeutics' oral sickle cell candidate HPPD. In preclinical studies, the first-in-class Nrf2/Bach1 modulator increased fetal hemoglobin and reduced oxidative stress and red blood cell sickling. The company noted that in those studies, the fetal hemoglobin increase was seen in a time- and dose-dependent manner, and effects were comparable to or better than hydroxy urea.